Condition

HER2 + Breast Cancer clinical trials and research

• 16Clinical trials
• 3NIH research projects
• 13Countries

Newest HER2 + Breast Cancer clinical trials

All recruiting trials (16)

• Oral paclitaxel with anti-HER2 therapy in HER2-positive breast cancer before surgery

  This trial tests a paclitaxel oral solution given with trastuzumab and pertuzumab to see if a safe dose can be found for women with HER2-positive breast cancer before they have surgery.

  Recruiting Phase 1/2 The Affiliated Hospital Of Guizhou Medical University · Guiyang, Guizhou · NCT07739511

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression

  This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.

  Recruiting Phase 4 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07600164

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

• HLX22 plus HLX87 as first-line treatment for HER2-positive recurrent or metastatic breast cancer

  This will test whether combining HLX22 with HLX87 helps adults with HER2-positive recurrent or metastatic breast cancer when given as a first-line treatment.

  Recruiting Phase 2/3 Shanghai Henlius Biotech · Beijing, Beijing Municipality · NCT07294508

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• First human use of [177Lu]Lu-ABY-271 to target HER2-positive metastatic breast cancer

  This first-in-human Phase 1 test will see if the radiopharmaceutical [177Lu]Lu-ABY-271 is safe and how it distributes in the body for people with HER2-positive metastatic breast cancer.

  Recruiting at 3 sites Phase 1 Affibody · Gothenburg and 2 other locations · NCT07081555

• RC48 with bevacizumab or pyrotinib for HER2-positive metastatic breast cancer after T-Dxd failure

  This trial will try RC48 together with either bevacizumab or pyrotinib in adults with HER2-positive metastatic breast cancer whose disease has progressed after trastuzumab deruxtecan (T-Dxd).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07065435

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Understanding breast cancer response during pre-surgery treatment

  This study is trying to see how breast cancer responds to treatment before surgery by looking at tissue and blood samples from patients to find out what factors might affect their recovery and risk of cancer coming back.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT06681064

• Registry for HER2-positive breast cancer patients

  This study is collecting information from people with HER2-positive breast cancer to see how different factors affect their treatment outcomes and overall care.

  Recruiting University of Kansas Medical Center · Overland Park, Kansas and 5 other locations · NCT06603597

• Evaluating IAM1363 for HER2-related cancers

  This study is testing a new treatment called IAM1363 to see if it can help people with advanced cancers that have changes in the HER2 gene.

  Recruiting at 53 sites Phase 1 Iambic Therapeutics, Inc · La Jolla, California and 52 other locations · NCT06253871

• Adding targeted radiation therapy to drug treatment for breast cancer

  This study is testing whether adding targeted radiation therapy to regular drug treatment can help people with a specific type of breast cancer keep their disease from getting worse or spreading.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT05534438

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

NIH-funded research (3)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• BRD8's role in hormone-receptor positive, HER2-positive breast cancer

  This project looks at whether targeting a protein called BRD8 can help people with hormone-receptor positive, HER2-positive breast cancer respond better to HER2 treatments.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11284108

• Understanding how BRD8 affects hormone receptor-positive and HER2-positive breast cancer

  This study is looking into how a protein called BRD8 affects breast cancer that is both hormone receptor-positive and HER2-positive, to find out why some patients don’t respond well to current treatments and to discover new ways to help them feel better.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11095727

• Targeting lipid metabolism to improve treatment for HER2+ breast cancer that has spread to the brain

  This study is looking at how to make treatments work better for people with HER2 positive breast cancer that has spread to the brain by finding ways to block the cancer cells' use of fats to grow, which could help existing therapies be more effective.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11079642

Related topics

Quick answers

How many HER2 + Breast Cancer clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in United States (7 trials), China (6 trials), United Kingdom (4 trials), Italy (4 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 3, Phase 4: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →